Search alternatives:
largest decrease » largest decreases (Expand Search), marked decrease (Expand Search)
larger decrease » marked decrease (Expand Search)
mean decrease » a decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
Showing 1,581 - 1,600 results of 123,309 for search '(( a ((we decrease) OR (mean decrease)) ) OR ( i ((largest decrease) OR (larger decrease)) ))', query time: 1.48s Refine Results
  1. 1581
    Awareness of disabilities in pharmacy program recruitment material: are we doing enough?

    Awareness of disabilities in pharmacy program recruitment material: are we doing enough? by Hussain, Farhat Naz

    Published 2020
    Get full text
    Get full text
    Save to List
    Saved in:
  2. 1582
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  3. 1583
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  4. 1584
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  5. 1585
    Interaction strength in plant-pollinator networks: Are we using the right measure?

    Interaction strength in plant-pollinator networks: Are we using the right measure? by Roberto Novella-Fernandez (8119745)

    Published 2019
    “…Interaction evenness also decreased strongly with the visit-based approach. We conclude that accounting for the number of flowers visited per encounter provides a more ecologically relevant measure of interaction strength. …”
    Save to List
    Saved in:
  6. 1586
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  7. 1587
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  8. 1588
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  9. 1589
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  10. 1590
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  11. 1591
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  12. 1592
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  13. 1593
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  14. 1594
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  15. 1595
    Estimated marginal means for changes in outcome parameters A, B, C, D.

    Estimated marginal means for changes in outcome parameters A, B, C, D. by Benjamin Udoka Nwosu (476930)

    Published 2015
    Save to List
    Saved in:
  16. 1596
    <i>In vivo</i> and long-term chaperone activity assessment of wild-type and p.R163C mutant αB-crystallin.

    <i>In vivo</i> and long-term chaperone activity assessment of wild-type and p.R163C mutant αB-crystallin. by Aref Baharvand (21713886)

    Published 2025
    Save to List
    Saved in:
  17. 1597
    NTM cells treated with TGFβ1 show increased expression of COL1A1 and DNMT1 and decreased expression of RASAL1.

    NTM cells treated with TGFβ1 show increased expression of COL1A1 and DNMT1 and decreased expression of RASAL1. by Fiona McDonnell (2636635)

    Published 2016
    “…</b> Upon investigation of mRNA expression of COL1A1, DNMT1 and RASAL1 by qPCR, we found that COL1A1 (P<0.05) and DNMT1 were increased and RASAL1 (P<0.05) was decreased in the cells treated with TGFβ1. …”
    Save to List
    Saved in:
  18. 1598
    S1 File -

    S1 File - by Yashengnan Sun (12501626)

    Published 2022
    Save to List
    Saved in:
  19. 1599
    Mean posterior estimates for parameters of interest for each simulated dataset varying across date resolution.

    Mean posterior estimates for parameters of interest for each simulated dataset varying across date resolution. by Leo A. Featherstone (21078333)

    Published 2025
    Save to List
    Saved in:
  20. 1600
    Diverse functional elements of Env respond differently to XBP1s induction.

    Diverse functional elements of Env respond differently to XBP1s induction. by Jimin Yoon (9646685)

    Published 2022
    Subjects:
    Save to List
    Saved in:

Search Tools: